Page last updated: 2024-09-05

lapatinib and ha14-1

lapatinib has been researched along with ha14-1 in 1 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (ha14-1)	Trials (ha14-1)	Recent Studies (post-2010) (ha14-1)
1,919	305	1,442	104	0	31

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Berger, M; Lipton, A; Planas-Silva, MD; Viallet, J; Witkoski, A; Witters, LM	1

Other Studies

1 other study(ies) available for lapatinib and ha14-1

Article	Year
Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncology reports, 2007, Volume: 17, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Breast Neoplasms; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Indoles; Lapatinib; Nitriles; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2	2007

Article

Year

Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.

Oncology reports, 2007, Volume: 17, Issue:2

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzopyrans; Breast Neoplasms; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Humans; Indoles; Lapatinib; Nitriles; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Quinazolines; Receptor, ErbB-2

2007